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Abstract
Background: The first large-scale meta-analysis of published genome-wide association studies (GWAS) in Parkinson’s
disease (PD) identified 5 new genetic loci (ACMSD, STK39, MCCC1/LAMP3, SYT11, and CCDC62/HIP1R). Very recently, a large-
scale replication and heterogeneity study also reported that STK39 and CCDC62/HIP1R increased risk of PD in Asian and
Caucasian populations. However, their roles still remain unclear in a Han Chinese population from mainland China.
Methods: We examined genetic associations of STK39 rs2102808 and CCDC62/HIP1R rs12817488 with PD susceptibility in a
Han Chinese population of 783 PD patients and 725 controls. We also performed further stratified analyses by the age of
onset and accomplished in-depth clinical characteristics analyses between the different genotypes for each locus.
Results: No significant differences were observed in the minor allele frequency (MAF) among cases and controls at the two
loci (STK39 rs2102808: OR = 1.06, 95% CI = 0.91, 1.23, P= 0.467; CCDC62/HIP1R rs12817488: OR = 0.88, 95% CI = 0.76, 1.01,
P= 0.072). Subgroup analyses by the age of onset also showed no significant differences among different subgroups of the
two loci. In addition, minor allele carriers cannot be distinguished from non-carriers based on their clinical features at the
two loci.
Conclusions: We are unable to demonstrate the association between STK39 and CCDC62/HIP1R and PD susceptibility in a
Han Chinese population from mainland China. Additional replication studies in other populations and functional studies are
warranted to better validate the role of the two new loci in PD risk.
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Introduction
Parkinson’s disease (PD, OMIM #168600) is the second most
common adult-onset neurodegenerative disorder involving not
only motor impairment but also deficits in behavior, cognition,
and daily function [1]. Fewer than 5% of all PD cases can be
attributed to genetic mutations in a-synuclein and the other known
PD genes [2]. However, the vast majority of PD cases are
considered idiopathic, whose specific pathogenesis remains to be
elucidated. Understanding the genetic architecture of PD might
provide valuable insights into individual risk predictions and gene
therapy for PD in the near future.
With the recent developments of high throughput genotyping
and genome-wide association studies (GWAS), tremendous
progress was made in our understanding of the genetic basis for
this complex disorder [3]. Up to now, several GWAS and many
candidate gene studies have provided consistent associations with
SNCA andMAPT [4–16], with some evidence for the role of BST1,
GAK/DGKQ, and the HLA region in PD susceptibility [7,11–
13,16]. The three recent meta-analyses reported eleven new loci:
ACMSD, STK39, MCCC1/LAMP3, SYT11, CCDC62/HIP1R,
PARK16, STX1B, FGF20, STBD1, GPNMB, and RIT2 [10,17–
18]. Hereafter, a large-scale replication and heterogeneity study
also reported that STK39 and CCDC62/HIP1R increased risk of
PD in Asian and Caucasian populations [19]. In their study, Asian
populations include a relatively large sample size from Hong
Kong, Singapore, Taiwan, Korea, and Japan [19]. Notably, these
studies did not include the Han Chinese population from
mainland China.
To provide more evidence into genuine loci contributing to PD
across diverse populations, we conducted a case-control study to
examine the genetic associations of STK39 (serine/threonine
kinase 39, rs2102808) and CCDC62/HIP1R (Coiled-coil domain
containing 62/Huntingtin-interacting protein 1-related,
rs12817488) among Han Chinese in mainland China. We also
performed further stratified analyses according to the age of onset
and accomplished in-depth clinical characteristics analyses be-
tween the different genotypes for each locus.
PLOS ONE | www.plosone.org 1 November 2013 | Volume 8 | Issue 11 | e79211
Materials and Methods
Subjects
The study population included 1508 ethnic Han Chinese
subjects comprising 783 sporadic PD patients (448 males, 335
females) and 725 controls (387 males, 338 females), all of whom
were recruited from the Department of Neurology of the West
China Hospital, Sichuan University. All patients (the mean age at
onset 54.19610.61, range 30–89) met United Kingdom Parkin-
son’s Disease Society Brain Bank clinical diagnostic criteria for PD
as determined by two movement disorder specialists [20], except
that patients who had an age at onset younger than 30 years.
Sporadic PD was defined as PD without a family history of disease.
Healthy control individuals (the mean age 55.26612.85, range
30–91) of similar race, gender, and age from the same region as
the PD patients were included. All subjects were divided into two
subgroups according to the age of onset (,50 years of age and
$50 years of age). The study was approved by the Ethics
Committee of Sichuan University. All participants or their legal
surrogates signed informed consent. DNA was extracted from
venous blood using standard methods.
Genetic Analysis
STK39 (rs2102808). Genotyping was performed using a
matrix-assisted laser desorption/ionization time-of-flight
(MALDI-TOF) mass spectrometry on a MassArray system
(Sequenom, San Diego, CA, USA) for STK39 rs2102808.
Approximately 15 ng of genomic DNA was used to genotype
each sample. Briefly, locus-specific polymerase chain reaction
(PCR) and detection primers for the MALDI-TOF analysis of the
STK39 gene target fragment were designed using the MassArray
Assay Design 3.0 software (Sequenom, San Diego, CA, USA). The
sample DNAs were amplified by primers flanking the targeted
sequence, followed by dephosphorylation and allele-specific
primer extension. Eluted extension products were loaded to the
dried matrix and finally subjected to MALDI-TOF mass
spectrometry. The resultant data were analyzed by the Sequenom
MassArray Typer software (Sequenom, San Diego, CA, USA).
CCDC62/HIP1R (rs12817488). Genotyping was performed
by using polymerase chain reaction followed by Restriction
Fragment Length Polymorphism (PCR-RFLP) with MspI (Fe-
mentas) for CCDC62/HIP1R rs12817488. A 334 bps fragment was
amplified by the following primer pair: 59TTTGGAGGCTAAG-
GAAGGG39 (forward) and 59TTTGGGATGT-
GAAGTTTGGCA39 (reverse). The PCR products were digested
overnight with MspI at 37uC and electrophoresed on 2% agarose
gel and visualized with ethidium bromide. The rs12817488 variant
creates a MspI restriction site which cuts the normal 334 bps PCR
products into fragments of 174 bps and171 bps. The AA genotype
gave a single band of 334 bps, the AG genotype two bands of
334 bps+174 bps+171 bps and the GG genotype a mixed band of
174 bps+171 bps. 10% of samples were randomly selected for
replication assays, the final results of which were completely
concordant with the original results.
Statistical Analysis
We assessed each locus for Hardy-Weinberg equilibrium (HWE)
in cases and controls separately with an exact test. Differences
between allelic and genotype frequencies in the patients and
controls were compared through a Chi-squared test. The two-
tailed Student’s t-test was used to compare the mean age between
the different genotypes. A two-tailed P-value #0.05 was consid-
ered statistically significant. Statistical analysis was performed
using the Statistical Package for the Social Sciences version 16.0
(SPSS, Chicago, IL, USA) for Windows. For power estimations we
used NCSS-PASS software (NCSS, Kaysville, Utah, USA). Odd
Ratios (ORs) of STK39 rs2102808 and CCDC62/HIP1R
rs12817488 were, respectively, 1.28 and 1.16 in the discovery
phase of the original GWAS meta-analysis [10]. Additionally,
based on the minor allele frequency (MAF) reported by our own
study in Han Chinese controls, estimated power was high for
STK39 (,91%), and modest for CCDC62/HIP1R (,55%).
Results
Data on a total of 1508 subjects including 783 cases and 725
controls were used for analysis. None of the single nucleotide
polymorphisms (SNPs) departed from HWE in patients and
controls. The allele frequencies of each SNP are summarized in
Table 1 between cases and controls.
No significant differences were observed in the minor allele
frequency among cases and controls at the two loci (rs2102808:
OR=1.06, 95% CI= 0.91, 1.23, P=0.467; rs12817488:
OR=0.88, 95% CI= 0.76, 1.01, P=0.072). In STK39
(rs2102808), subjects with GT+TT genotypes was not significantly
different from those with GG genotype (OR=0.96, 95%
CI= 0.78, 1.17, P=0.657). At the same time, subjects with
AG+GG genotypes have no significant differences compared to
those with AA genotype at CCDC62/HIP1R rs12817488
(OR=0.89, 95% CI= 0.71, 1.11, P=0.286). In addition, further
stratified analyses according to the age of onset also showed that
the associations were not significant among the younger age group
and the older age group in STK39 and CCDC62/HIP1R (Table 2).
We also compared the clinical characteristics of PD cases that
carried the minor allele with PD Cases who did not carry it (Table
3). However, there was no significant difference in the clinical
presentation for gender, age of onset, onset symptoms at STK39
rs2102808 and CCDC62/HIP1R rs12817488.
Discussion
The first large-scale meta-analysis of GWAS in PD identified 5
new PD genetic loci (ACMSD, STK39, MCCC1/LAMP3, SYT11,
and CCDC62/HIP1R) [10]. Very recently, a case-control replica-
tion study provided support for all these loci in a relatively
homogenous Scandinavian population [21]. Moreover, a large
replication study [19] and acomprehensive meta-analysis from the
PDGene database [22] also investigated the same associations for
all 5 loci except ACMSD and subgroup analysis by ethnicity also
showed similar effect size estimates for STK39, CCDC62/HIP1R,
and MCCC1/LAMP3 in Asian and Caucasian populations [19].
Besides, the other two intronic SNPs, rs3754775 and rs6740826 in
STK39, showed the strongest evidence of association using an
overall MAF threshold of 2% or higher to identify rare genetic
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variants in a relatively genetically homogeneous Ashkenazi Jewish
population (OR=2.12, 95% CI=1.24, 3.62, P=0.005) [8].
In view of the population-specific heterogeneity, we accom-
plished a case-control study included 1508 subjects to further
explore the role of two newly identified genetic variants (STK39
rs2102808 and CCDC62/HIP1R rs12817488) in risk of PD in a
Han Chinese population from mainland China. Conversely, we
are unable to replicate the association between STK39 rs2102808
and CCDC62/HIP1R rs12817488 and PD susceptibility. Subgroup
analyses by age of onset also showed no significant differences
among different subgroups of the two loci. In addition, minor
allele carriers cannot be distinguished from non-carriers based on
their clinical features for gender, age of onset, onset symptoms at
the two loci.
Our finding should be interpreted with caution as our modest
sample size results in only modest power for some alleles with very
small effect sizes. This is especially for CCDC62/HIP1R
rs12817488. Future multi-site efforts and meta-analyses will be
useful. Genetic heterogeneity across diverse populations may also
explain the variances between studies. Our selected SNPs in our
cohort might not be genuine functional variants, or the pattern of
linkage disequilibrium (LD) might differ so that they are no longer
‘‘tagging’’ some unidentified functional variants effectively [21]. It
is worth noting that the MAF for STK39 rs2102808 differs
markedly from that reported in the original meta-analysis of
GWAS published in the Lancet in 2011 (0.35 vs. 0.13). This
highlights possibility of population heterogeneity, which may
underlie nonreplication in independent studies. Gene-environment
and gene-geneinteractions may also be confounding variables?
Taken together, sequencing or comprehensive tag-SNP genotyp-
ing and imputation across different populations will probably be
utilized to disentangle how variation contributes to PD risk in
future studies [21].
The STK39 has been associated with hypertension, autism, and
early-stage non-small-cell lung cancer [23–25]. The STK39
encodes a serine/threonine kinase (SPAK/PASK/STE20-SPS1
homolog) of 547-amino acids with roles in stress signals, ion
homoeostasis, and inflammatory status [26–29]. In fact, CCDC62/
HIP1R involves two diverse genes [30]. CCDC62 is linked to
estrogen receptor transactivation, cyclin D1 expression in prostate
cancer cells, and antibodies to this protein develop in a variety of
cancers [31–32]. Additionally, the protein product of HIP1R is
involved in clathrin-mediated endocytosis, actin dynamics, intrin-
sic cell death pathway, accurate distribution of chromosomes [33–
36]. It appears to interacted with huntingtin to modulate
polyglutamine-induced neuronal dysfunction in transgenic nema-
todes Huntington model [37]. However, the ture role of these
genes awaits discovery in the pathophysiologic pathway of PD.
In conclusion, our study from mainland China demonstrates
that STK39 (rs2102808) and CCDC62/HIP1R (rs12817488) do not
Table 2. Association between thetwo genetic loci and PD.





STK39 rs2102808 GG GT+TT
PDa 783 335 (42.8) 448 (57.2) 0.96 (0.78,
1.17)
0.657
EOPDb 262 104 (39.7) 158 (60.3) 0.96 (0.67,
1.39)
0.851
LOPDc 521 231 (44.3) 290(55.7) 0.95 (0.74,
1.21)
0.654
Controls 725 302 (41.7) 423 (58.3)
Controls ,50 yr 229 89 (38.9) 140 (61.1)




PD 760 234 (30.8) 526 (69.2) 0.89 (0.71,
1.11)
0.286
EOPD 260 78 (30.0) 182 (70.0) 0.78 (0.52,
1.16)
0.220
LOPD 500 156(31.2) 344(68.8) 0.93(0.71,
1.23)
0.622
Controls 708 200 (28.2) 508 (71.8)
Controls ,50 yr 224 56 (25.0) 168 (75.0)
Controls $50 yr 484 144(29.8) 340(70.2)
EOPD, early onset Parkinson’s disease; LOPD, late onset Parkinson’s disease.
aPatients compared with controls by genotype.
bEOPD Patients compared with controls (,50 years) by genotype.
cLOPD Patients compared with controls ($50 years) by genotype.
doi:10.1371/journal.pone.0079211.t002
Table3. Clinical Characteristics of PD Patients between minor
allele carriers and non-carriers.
Gentype P-value
STK39 rs2102808 GG GT+TT
General characteristics
Gender
Male (%) 190 (56.7) 258 (57.6) 0.807
Female (%) 145 (43.3) 218 (42.4)
Age at onseta
Total cohort 54.75610.59 53.77610.62 0.198
EOPD 42.4764.82 42.4464.88 0.955
LOPD 60.2867.31 59.9467.28 0.594
Onset symptoms
Resting tremor (%) 167 (49.9) 230 (51.3) 0.589
Bradykinesia-rigidity (%) 126(37.6) 152 (33.9)
Mixed symptoms (%) 16 (4.8) 21 (4.7)






Male (%) 128 (54.7) 308 (58.6) 0.321
Female (%) 106 (45.3) 218 (41.4)
Age at onseta
Total cohort 54.23610.70 54.12610.75 0.894
EOPD 42.2365.10 42.5364.78 0.648
LOPD 60.2367.1 60.2567.48 0.982
Onset symptoms
Resting tremor (%) 112 (47.9) 270 (51.3) 0.313
Bradykinesia-rigidity (%) 92 (39.3) 180 (34.2)
Mixed symptoms (%) 7 (3.0) 28 (5.3)
Others(%)b 23 (9.8) 48 (9.1)
aData are mean 6 SD.
bIncluding pain, weakness, symptoms of autonomic dysfunction and so on.
doi:10.1371/journal.pone.0079211.t003
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appear to influence PD risk. Subgroup analyses also showed no
significant differences among different subgroups of the two loci.
Furthermore, minor allele carriers cannot be distinguished from
non-carriers based on their clinical features at the two loci.
Additional replication studies in other populations and functional
studies are warranted to better validate the role of the two new loci
in PD susceptibility.
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